The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 175
- 试验地点
- 1
- 主要终点
- miRNA
研究概览
简要总结
For acute coronary syndrome patients undergoing cardiac catheterization after stenting, we will give dual antiplatelet drugs (dual antiplatelet agents) therapy, the choice of the basis of medical criteria (clinical guidelines) routine as aspirin + clopidogrel or aspirin + ticagrelor, according to medical guidelines currently no other disposal alternative proposal (unless adverse drug tolerance or bleeding can not be administered); idea of this experiment for acute coronary syndrome or conventional cardiac catheterization after stenting, platelet miRNA expression (miR-96 , miR-200b, miR-495, miR-107) after cardiac catheterization and interventional treatment of clopidogrel or ticagrelor acceptance of platelet reactivity (PRU) correlation values (given clopidogrel or ticagrelor determined by the clinician, the patient follow-up experiment to track only and observation), aims to explore under different platelet reactivity (hyper-reactive or hypo-reactive), their differences in miRNA performance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 90 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1 under DAPT (dual antiplatelet therapy) of stable angina patients for elective stent implantation.
- •DAPT 24 hours after treatment PRU (platelet activity units) values. (Drug unresponsive patients was defined as PRU> 235).
排除标准
- •1.Not suitable for the treatment of patients with DAPT. (Active peptic ulceration or bleeding) 2 patients of aspirin, clopidogrel, ticagrelor, cilostazol medication intolerance.
- •3 contraindications for aspirin, clopidogrel, ticagrelor, cilostazol drug usage (such as heart failure patients not suitable for use cilostazol).
研究组 & 干预措施
control
normal subjects.
干预措施: miRNA after 1 week (Procedure)
control
normal subjects.
干预措施: miRNA after 1 month (Procedure)
control
normal subjects.
干预措施: miRNA within 24hr (Procedure)
clopidogrel
subjects received clopidogrel 75mg qd.
干预措施: miRNA within 24hr (Procedure)
clopidogrel
subjects received clopidogrel 75mg qd.
干预措施: miRNA after 1 week (Procedure)
clopidogrel
subjects received clopidogrel 75mg qd.
干预措施: miRNA after 1 month (Procedure)
ticagrelor
subjects received ticagrelor 90mg qd.
干预措施: miRNA within 24hr (Procedure)
ticagrelor
subjects received ticagrelor 90mg qd.
干预措施: miRNA after 1 week (Procedure)
ticagrelor
subjects received ticagrelor 90mg qd.
干预措施: miRNA after 1 month (Procedure)
cilostazol
subjects received cilostazol 100mg bid.
干预措施: miRNA within 24hr (Procedure)
cilostazol
subjects received cilostazol 100mg bid.
干预措施: miRNA after 1 week (Procedure)
cilostazol
subjects received cilostazol 100mg bid.
干预措施: miRNA after 1 month (Procedure)
结局指标
主要结局
miRNA
时间窗: 7 days
miRNA-365-3p measure by Roche miRNA kits; PRP(platelet riched plasma) isolated miRNA by isolation Kit, then havest in cDNA synthesis Kit; then perform RT PCR. .
次要结局
未报告次要终点
研究者
Yueh-Chung, Chen
chief of ICU
Taipei City Hospital
